About ZS Pharma (NASDAQ:ZSPH)
ZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company's zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. The Company has completed Phase III development of its product candidate, sodium zirconium cyclosilicate (ZS-9), for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed three clinical studies with ZS-9 for patients with hyperkalemia, including patients with chronic kidney disease (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS) inhibitor therapy.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-66.24%
Return on Assets-58.88%
ZS Pharma (NASDAQ:ZSPH) Frequently Asked Questions
What is ZS Pharma's stock symbol?
ZS Pharma trades on the NASDAQ under the ticker symbol "ZSPH."
How were ZS Pharma's earnings last quarter?
ZS Pharma Inc (NASDAQ:ZSPH) released its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.04) by $0.63. View ZS Pharma's Earnings History.
Who are some of ZS Pharma's key competitors?
Some companies that are related to ZS Pharma include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Medivation (MDVN), Bioverativ (BIVV), Kite Pharma (KITE), Juno Therapeutics (JUNO), bluebird bio (BLUE), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Beigene (BGNE), Shire-Nps Pharmaceuticals (NPSP), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), TESARO (TSRO), AveXis (AVXS), GW Pharmaceuticals PLC- (GWPH) and Auspex Pharmaceuticals (ASPX).
How do I buy ZS Pharma stock?
Shares of ZS Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact ZS Pharma?
ZS Pharma's mailing address is 508 Wrangler Dr Ste 100, COPPELL, TX 75019-7609, United States. The biopharmaceutical company can be reached via phone at +1-650-4584100.
MarketBeat Community Rating for ZS Pharma (ZSPH)MarketBeat's community ratings are surveys of what our community members think about ZS Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ZS Pharma (NASDAQ:ZSPH) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
ZS Pharma (NASDAQ:ZSPH) Earnings History and Estimates Chart
ZS Pharma (NASDAQ ZSPH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
ZS Pharma (NASDAQ:ZSPH) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ZS Pharma (NASDAQ:ZSPH)
No dividend announcements for this company have been tracked by MarketBeat.com
ZS Pharma (NASDAQ ZSPH) Insider Trading and Institutional Ownership History
ZS Pharma (NASDAQ ZSPH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/21/2015||Todd A. Creech||CFO||Sell||70,000||$49.84||$3,488,800.00|| |
|6/8/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||175,427||$57.86||$10,150,206.22|| |
|6/4/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||111,597||$57.30||$6,394,508.10|| |
|6/2/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||296,423||$58.00||$17,192,534.00|| |
|6/23/2014||A/S Novo||Insider||Buy||275,000||$18.00||$4,950,000.00|| |
|6/23/2014||Guy P Nohra||Director||Buy||200,000||$18.00||$3,600,000.00|| |
|6/23/2014||Park Bioventures Lp Devon||Major Shareholder||Buy||160,000||$18.00||$2,880,000.00|| |
ZS Pharma (NASDAQ ZSPH) News Headlines
ZS Pharma (NASDAQ:ZSPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ZS Pharma (NASDAQ:ZSPH) Income Statement, Balance Sheet and Cash Flow Statement
ZS Pharma (NASDAQ ZSPH) Stock Chart for Tuesday, January, 23, 2018